PsiThera
PsiThera is advancing programs across multiple targets from the TNF superfamily and beyond, where no oral therapies currently exist.
$47.5M Series A ·
Led by Lightstone Ventures · Source: startupintros.com
Funding history ↓Signals
Website registeredNov 18, 2025 (12 months old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series A | $47.5M | startupintros.com |
Timeline
- Website created
Founders and team
WS
Woody Sherman FounderES
Eric Shaff President and Chief Executive Officer
Investors
EEurofarma
LLightstone Ventureslead investor
RRoivant Sciences
SSamsara Biocapitallead investor
YYK Bioventures
Companies like PsiThera
NNormunity$75M Series B+ · Jan 2025
CCelea Therapeutics$180M Series A · Jul 2026
AAlzheon$100M Series B+ · Apr 2022
DDeepCure$24M Series A · Apr 2024
CCasma Therapeutics$46M Series B+ · Nov 2022
FFrontier MedicinesSeries B+ · Aug 2025
Other companies backed by Lightstone Ventures
AAmber Therapeutics$100M Series A · Jul 2026
PProVerum$80M Series B+ · Aug 2025
TTagworks Pharmaceuticals$65M Series A · Jun 2023
Lightstone Ventures portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/psithera (get a free API key).